Format

Send to

Choose Destination
Cell Stem Cell. 2019 Jan 3;24(1):25-40. doi: 10.1016/j.stem.2018.11.017. Epub 2018 Dec 27.

Targeting Cancer Stemness in the Clinic: From Hype to Hope.

Author information

1
Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
2
Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
3
Division of Hematology, Department of Medicine, Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
4
Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH 44192, USA.
5
Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH 44192, USA. Electronic address: lathiaj@ccf.org.

Abstract

Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining tumors by manipulating genetic and non-genetic factors to metastasize, resist treatment, and maintain the tumor microenvironment. Understanding the key traits and mechanisms of CSC survival provides opportunities to improve patient outcomes via improved prognostic models and therapeutics. Here, we review the clinical significance of CSCs and results of potential CSC-targeting therapies in various cancers. We discuss barriers to translating cues from pre-clinical models into clinical applications and propose new strategies for rational design of future anti-CSC trials.

KEYWORDS:

CD123; Notch; cancer stem cell; differentiation therapies; hedgehog; niche

PMID:
30595497
DOI:
10.1016/j.stem.2018.11.017

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center